Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theodore C Pierson

Showing results (121-130 of 164) with videos related to

Pageof 17
Sort By:
The Journal of Experimental Medicine|April 8, 2021
Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flavivirusesLaura A VanBlargan, John M Errico, Natasha M Kafai, et al.
Journal of Virology|August 4, 2021
Levels of Circulating NS1 Impact West Nile Virus Spread to the BrainAlex W Wessel, Kimberly A Dowd, Scott B Biering, et al.
Vaccine|November 6, 2025
Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to developmentRandall J Nett, Aaron C Brault, Amy J Lambert, et al.
Science Translational Medicine|June 3, 2026
Neutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target receptor binding sitesDaniel L Moss, Jiaxuan Cheng, Peter W Krug, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2023
prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesisKimberly A Dowd, Devika Sirohi, Scott D Speer, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2024
pr-independent biogenesis of infectious mature Zika virus particlesKimberly A Dowd, Michelle Schroeder, Egan Sanchez, et al.
The Journal of Infectious Diseases|January 15, 2008
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trialJulie E Martin, Theodore C Pierson, Sarah Hubka, et al.
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
Cell Host & Microbe|October 5, 2021
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunityRita E Chen, Brittany K Smith, John M Errico, et al.
Vaccines|August 28, 2025
Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 VaccinesCheng Cheng, Jeffrey C Boyington, Edward K Sarfo, et al.
Pageof 17

Showing results (121-130 of 164) with videos related to

Sort By:
Pageof 17
The Journal of Experimental Medicine|April 8, 2021
Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flavivirusesLaura A VanBlargan, John M Errico, Natasha M Kafai, et al.
Journal of Virology|August 4, 2021
Levels of Circulating NS1 Impact West Nile Virus Spread to the BrainAlex W Wessel, Kimberly A Dowd, Scott B Biering, et al.
Vaccine|November 6, 2025
Summary of human West Nile virus vaccine meeting, 2024: Investigating barriers to developmentRandall J Nett, Aaron C Brault, Amy J Lambert, et al.
Science Translational Medicine|June 3, 2026
Neutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target receptor binding sitesDaniel L Moss, Jiaxuan Cheng, Peter W Krug, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 13, 2023
prM-reactive antibodies reveal a role for partially mature virions in dengue virus pathogenesisKimberly A Dowd, Devika Sirohi, Scott D Speer, et al.
Biorxiv : the Preprint Server for Biology|October 7, 2024
pr-independent biogenesis of infectious mature Zika virus particlesKimberly A Dowd, Michelle Schroeder, Egan Sanchez, et al.
The Journal of Infectious Diseases|January 15, 2008
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trialJulie E Martin, Theodore C Pierson, Sarah Hubka, et al.
Lancet (London, England)|August 19, 2014
Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trialLee-Jah Chang, Kimberly A Dowd, Floreliz H Mendoza, et al.
Cell Host & Microbe|October 5, 2021
Implications of a highly divergent dengue virus strain for cross-neutralization, protection, and vaccine immunityRita E Chen, Brittany K Smith, John M Errico, et al.
Vaccines|August 28, 2025
Systemic and Mucosal Humoral Immune Responses to Lumazine Synthase 60-mer Nanoparticle SARS-CoV-2 VaccinesCheng Cheng, Jeffrey C Boyington, Edward K Sarfo, et al.
Pageof 17